Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | PPARA | Q07869 | 9/20 | 0.41 |
| ▸ | PPARD | Q03181 | 5/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PLAU | P00749 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | FABP4 | P15090 | 1/20 | 0.38 |
| ▸ | PLG | P00747 | 1/20 | 0.38 |
| ▸ | PLAT | P00750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3376959 | 0.90 | PPARG (0.46) | PPARGPTPN1PPARAPPARDNPC1 | |
| SCHEMBL3378337 | 0.88 | PPARG (0.47) | PPARGPPARASMN1; SMN2FABP4 | |
| SCHEMBL3374136 | 0.88 | PPARG (0.49) | PPARGPPARAPPARDNPC1RAB9A | |
| SCHEMBL3376824 | 0.87 | PPARG (0.42) | PPARGPTPN1PPARAPPARDNPC1 | |
| SCHEMBL3376896 | 0.82 | PPARD (0.53) | PPARGPPARAPPARD | |
| SCHEMBL10663764 | 0.80 | SMN1; SMN2 (0.45) | PPARGPPARAPPARDSMN1; SMN2 | |
| SCHEMBL13069923 | 0.80 | PPARG (0.49) | PPARGPPARAPPARD | |
| SCHEMBL13070053 | 0.80 | RAB9A (0.42) | PPARGPPARAPPARDNPC1RAB9A | |
| SCHEMBL3376815 | 0.77 | PPARA (0.53) | PPARGPPARAPPARD | |
| SCHEMBL3375295 | 0.74 | PPARA (0.47) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1796665-B1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK SHARP & DOHME (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-1796665-B1 | COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS | MERCK SHARP & DOHME (US) | 2010-11-17 | — | — | EP | disclosed |
| US-7629372-B2 | Compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629372-B2 | Compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629372-B2 | Compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | MERCK & CO., INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | MERCK & CO., INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | MERCK & CO., INC. (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | LIPA, APOB, LCAT | PPARG 152/4885PTPN1 2789/4885PPARA 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.